Joint NDA Acceptance for Sintilimab and Fruquintinib in Chinese Renal Cell Carcinoma Treatment Innovent and HUTCHMED have announced the acceptance of a New Drug Application in China for a combination therapy aimed at advanced renal cell carcinoma, marking a significant milestone in treatment options.

Joint NDA Acceptance for Sintilimab and Fruquintinib in Chinese Renal Cell Carcinoma Treatment #China #Suzhou #renal_cancer #Sintilimab #Fruquintinib

FruBLOOM = real patients, real progress. Researchers are studying how fruquintinib works in the real world—and which biomarkers may predict better outcomes. Because the more we know, the better we can treat. #ASCO25 #Fruquintinib #FruBLOOM
👉: meetings.asco.org/abstracts-presentations/...